Multidrug-Resistant Tuberculosis: Challenges and Solutions

Multidrug-Resistant Tuberculosis (MDR-TB) has become a major global health challenge because there is limited scope of treatment options when rifampicin and isoniazid -two frontline drugs in standard TB treatment regiments are resistant.This resistance significantly impairs the effectiveness of present therapies and prolongs the time it takes to treat, increasing the cost burden and mortality rates in afflicted populations.Intrinsic drug resistance, formation of nonreplicating bacilli, poor vascularization of granulomatous lesions, poor clinical agent management, and genetic mutations of Mycobacterium tuberculosis genes are MDR-TB resistance mechanisms.As these factors complicate treatment outcomes, new types of interventions are needed to overcome barriers.Diagnostical tools and therapeutic strategies have also been advanced, including new drugs, combination regimens and new molecular diagnostic methods all have promising solutions.However, solutions to the treatment challenges need to be developed to address rapid diagnostics, effective drug delivery, and improved patient adherence.There is a need to find more sustainable and innovative ways to manage and successfully treat MDR-TB.